// App-Quantinova.ai

: Assessing the effectiveness of pirfenidone in changing the natural course of idiopathic pulmonary fibrosis: the data from European IPF Registry (eurIPFreg

Researchers

Presenter

  • Ekaterina Krauss

Principal Investigators

  • Silke Tello

  • Ruth C. Dartsch

  • Martina Korfei

  • Poornima Mahavadi

  • Mark Stoehr

  • Jochen Wilhelm

  • Raphael Majeed

  • Philippe Bonniaud

  • Carlo Vancheri

  • Athol U. Wells

  • Werner Seeger

  • Bruno Crestani

  • Andreas Guenther

Medical Centers

  • Reference Center for Rare Pulmonary Diseases, Centre Hospitalier Universitaire Dijon-Bourgogne, INSERMU1231, Université Bourgogne/Franche-Comté , Dijon, France

  • Dept. of Clinical and Molecular Biomedicine, Università degli Studi di Catania, Catania, Italy

  • Interstitial Lung Disease Unit, Royal Brompton Hospital, London, UK

  • Competence Center for Rare Pulmonary Diseases, Hopital Bichat, Paris, France

  • Universities of Giessen and Marburg Lung Center (UGMLC, Member of the German Center for Lung Research (DZL; European IPF Registry & Biobank (eurIPFreg, Agaplesion Lung Clinic Waldhof-Elgershausen, Greifenstein, Cardio-Pulmonary Institute (CPI,, Giessen, Germany

Locations

  • Germany

  • France

  • Italy

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

Disease

  • Idiopathic pulmonary fibrosis

Biomarkers

  • N/A

Drug/Treatment

  • Pirfenidone

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved